CRSP70 Inhibitors

CRSP70 inhibitors are chemicals that indirectly influence the activity of MED26, a component of the mediator complex in transcription regulation. These inhibitors primarily function by targeting various aspects of the transcription and RNA synthesis processes, thereby affecting the functional role of MED26. For example, Triptolide and α-Amanitin work by inhibiting components of the transcription machinery, like the XPB subunit of TFIIH and RNA polymerase II, respectively. This indirect method of action can alter MED26's involvement in transcription regulation. Similarly, DRB, a compound that inhibits transcription elongation, can impact the mediator complex's function, including MED26. Other chemicals in this class, such as Mithramycin A and Actinomycin D, bind to DNA and inhibit transcription, potentially affecting the role of MED26. Flavopiridol and 5,6-Dichlorobenzimidazole target the transcription elongation process and RNA polymerase II, respectively, which can indirectly influence MED26's activity. Compounds like I-BET151 and JQ1, which are BET bromodomain inhibitors, modulate transcriptional processes that involve MED26. In addition, Pladienolide B and Rocaglamide, by inhibiting the spliceosome SF3b complex and translation initiation, respectively, can indirectly impact MED26's role in transcription.